Melatonin Neurim European Union - English - EMA (European Medicines Agency)

melatonin neurim

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

CIRCADIN Israel - English - Ministry of Health

circadin

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

CIRCADIN Israel - English - Ministry of Health

circadin

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

SLENYTO 1 MG Israel - English - Ministry of Health

slenyto 1 mg

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 1 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

SLENYTO 5 MG Israel - English - Ministry of Health

slenyto 5 mg

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 5 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

Circadin European Union - English - EMA (European Medicines Agency)

circadin

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Slenyto European Union - English - EMA (European Medicines Agency)

slenyto

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psycholeptics - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

Circadin New Zealand - English - Medsafe (Medicines Safety Authority)

circadin

pharmacy retailing (nz) ltd t/a healthcare logistics - melatonin 2mg;  ;   - modified release tablet - 2 mg - active: melatonin 2mg     excipient: ammonio methacrylate copolymer calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate purified talc - monotherapy for the short term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Vigisom New Zealand - English - Medsafe (Medicines Safety Authority)

vigisom

pharmacy retailing (nz) ltd t/a healthcare logistics - melatonin 2mg;  ;   - modified release tablet - 2 mg - active: melatonin 2mg     excipient: ammonio methacrylate copolymer calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate purified talc - monotherapy for the short term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.